Cargando…
Association between the use of allopurinol and risk of increased thyroid-stimulating hormone level
Allopurinol is the first-line agent for patients with gout, including those with moderate‐to‐severe chronic kidney disease. However, increased thyroid-stimulating hormone (TSH) levels are observed in patients with long-term allopurinol treatment. This large-scale, nested case–control, retrospective...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8514499/ https://www.ncbi.nlm.nih.gov/pubmed/34645831 http://dx.doi.org/10.1038/s41598-021-98954-1 |
_version_ | 1784583402207313920 |
---|---|
author | Choi, Wona Yang, Yoon-Sik Chang, Dong-Jin Chung, Yeon Woong Kim, HyungMin Ko, Soo Jeong Yoo, Sooyoung Oh, Ji Seon Kang, Dong Yoon Yang, Hyeon-Jong Choi, In Young |
author_facet | Choi, Wona Yang, Yoon-Sik Chang, Dong-Jin Chung, Yeon Woong Kim, HyungMin Ko, Soo Jeong Yoo, Sooyoung Oh, Ji Seon Kang, Dong Yoon Yang, Hyeon-Jong Choi, In Young |
author_sort | Choi, Wona |
collection | PubMed |
description | Allopurinol is the first-line agent for patients with gout, including those with moderate‐to‐severe chronic kidney disease. However, increased thyroid-stimulating hormone (TSH) levels are observed in patients with long-term allopurinol treatment. This large-scale, nested case–control, retrospective observational study analysed the association between allopurinol use and increased TSH levels. A common data model based on an electronic medical record database of 19,200,973 patients from seven hospitals between January 1997 and September 2020 was used. Individuals aged > 19 years in South Korea with at least one record of a blood TSH test were included. Data of 59,307 cases with TSH levels > 4.5 mIU/L and 236,508 controls matched for sex, age (± 5), and cohort registration date (± 30 days) were analysed. An association between the risk of increased TSH and allopurinol use in participants from five hospitals was observed. A meta-analysis (I(2) = 0) showed that the OR was 1.51 (95% confidence interval: 1.32–1.72) in both the fixed and random effects models. The allopurinol intake group demonstrated that increased TSH did not significantly affect free thyroxine and thyroxine levels. After the index date, some diseases were likely to occur in patients with subclinical hypothyroidism and hypothyroidism. Allopurinol administration may induce subclinical hypothyroidism. |
format | Online Article Text |
id | pubmed-8514499 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-85144992021-10-14 Association between the use of allopurinol and risk of increased thyroid-stimulating hormone level Choi, Wona Yang, Yoon-Sik Chang, Dong-Jin Chung, Yeon Woong Kim, HyungMin Ko, Soo Jeong Yoo, Sooyoung Oh, Ji Seon Kang, Dong Yoon Yang, Hyeon-Jong Choi, In Young Sci Rep Article Allopurinol is the first-line agent for patients with gout, including those with moderate‐to‐severe chronic kidney disease. However, increased thyroid-stimulating hormone (TSH) levels are observed in patients with long-term allopurinol treatment. This large-scale, nested case–control, retrospective observational study analysed the association between allopurinol use and increased TSH levels. A common data model based on an electronic medical record database of 19,200,973 patients from seven hospitals between January 1997 and September 2020 was used. Individuals aged > 19 years in South Korea with at least one record of a blood TSH test were included. Data of 59,307 cases with TSH levels > 4.5 mIU/L and 236,508 controls matched for sex, age (± 5), and cohort registration date (± 30 days) were analysed. An association between the risk of increased TSH and allopurinol use in participants from five hospitals was observed. A meta-analysis (I(2) = 0) showed that the OR was 1.51 (95% confidence interval: 1.32–1.72) in both the fixed and random effects models. The allopurinol intake group demonstrated that increased TSH did not significantly affect free thyroxine and thyroxine levels. After the index date, some diseases were likely to occur in patients with subclinical hypothyroidism and hypothyroidism. Allopurinol administration may induce subclinical hypothyroidism. Nature Publishing Group UK 2021-10-13 /pmc/articles/PMC8514499/ /pubmed/34645831 http://dx.doi.org/10.1038/s41598-021-98954-1 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Choi, Wona Yang, Yoon-Sik Chang, Dong-Jin Chung, Yeon Woong Kim, HyungMin Ko, Soo Jeong Yoo, Sooyoung Oh, Ji Seon Kang, Dong Yoon Yang, Hyeon-Jong Choi, In Young Association between the use of allopurinol and risk of increased thyroid-stimulating hormone level |
title | Association between the use of allopurinol and risk of increased thyroid-stimulating hormone level |
title_full | Association between the use of allopurinol and risk of increased thyroid-stimulating hormone level |
title_fullStr | Association between the use of allopurinol and risk of increased thyroid-stimulating hormone level |
title_full_unstemmed | Association between the use of allopurinol and risk of increased thyroid-stimulating hormone level |
title_short | Association between the use of allopurinol and risk of increased thyroid-stimulating hormone level |
title_sort | association between the use of allopurinol and risk of increased thyroid-stimulating hormone level |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8514499/ https://www.ncbi.nlm.nih.gov/pubmed/34645831 http://dx.doi.org/10.1038/s41598-021-98954-1 |
work_keys_str_mv | AT choiwona associationbetweentheuseofallopurinolandriskofincreasedthyroidstimulatinghormonelevel AT yangyoonsik associationbetweentheuseofallopurinolandriskofincreasedthyroidstimulatinghormonelevel AT changdongjin associationbetweentheuseofallopurinolandriskofincreasedthyroidstimulatinghormonelevel AT chungyeonwoong associationbetweentheuseofallopurinolandriskofincreasedthyroidstimulatinghormonelevel AT kimhyungmin associationbetweentheuseofallopurinolandriskofincreasedthyroidstimulatinghormonelevel AT kosoojeong associationbetweentheuseofallopurinolandriskofincreasedthyroidstimulatinghormonelevel AT yoosooyoung associationbetweentheuseofallopurinolandriskofincreasedthyroidstimulatinghormonelevel AT ohjiseon associationbetweentheuseofallopurinolandriskofincreasedthyroidstimulatinghormonelevel AT kangdongyoon associationbetweentheuseofallopurinolandriskofincreasedthyroidstimulatinghormonelevel AT yanghyeonjong associationbetweentheuseofallopurinolandriskofincreasedthyroidstimulatinghormonelevel AT choiinyoung associationbetweentheuseofallopurinolandriskofincreasedthyroidstimulatinghormonelevel |